A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100.
about
Novel approaches to inhibit HIV entryAMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agentSevere congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis.Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial.The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome.AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation.Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor.Challenges for heart disease stem cell therapy.Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.Pre-treatment of allogeneic bone marrow recipients with the CXCR4 antagonist AMD3100 transiently enhances hematopoietic chimerism without promoting donor-specific skin allograft tolerance.Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers.A systematic review and empirical analysis of the relation between dose and duration of drug action.Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Novel agents and approaches for stem cell mobilization in normal donors and patients.A Lentiviral CXCR4 overexpression and knockdown model in colorectal cancer cell lines reveals plerixafor-dependent suppression of SDF-1α-induced migration and invasion.Discovery of tetrahydroisoquinoline-based CXCR4 antagonists.G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer.The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines.CXCR4 in Cancer and Its Regulation by PPARgamma.Rac signal adaptation controls neutrophil mobilization from the bone marrow.CXCR₄antagonism as a therapeutic approach to prevent acute kidney injury.Distinct mobilization of leukocytes and hematopoietic stem cells by CXCR4 peptide antagonist LY2510924 and monoclonal antibody LY2624587.Plerixafor enables the safe, rapid, efficient mobilization of haematopoietic stem cells in sickle cell disease patients after exchange transfusion.Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
P2860
Q27013957-0B6F928A-2289-4487-A83F-84427845BB3CQ28286940-BFDBC7B7-DFE4-4638-AF47-6C061DB369FDQ30430294-F956740F-C7B6-4008-95B3-821EA8634FFCQ33573756-5F2ED66C-7E15-423E-8835-6D6B1198B172Q34207531-4A98F365-17C0-4F47-9BD9-5835182265FDQ35080100-FF0FC441-C93F-429F-9D36-C14C84233751Q35793034-86371878-07AF-4A14-98E5-180FD1FFB88DQ35808738-CB626AF9-25A0-4616-9CC5-118BC7982E8BQ35879000-CAF59113-32FD-4535-8790-18807D570992Q36157297-CB3AD398-FC1E-4C95-8817-F8684ECEA0F4Q36445393-6E78A3C5-DED7-4F9A-BF1A-11D66413CB5CQ37429295-495CA80C-6B02-4F2C-9138-B64DD58DF08EQ37606934-3A7AB2C3-9031-4949-AF81-DA7D879A854CQ37653639-2B8563FC-159E-4EF5-A3F7-9FA45C70CC8FQ37707195-FD4B57A8-439B-4C67-9420-0C607FC5B1F9Q37921284-F15ECE03-687C-4ECF-BB52-1056C0C6573DQ37923309-016A108A-2D88-43BE-8720-91C915650E4FQ39460665-95A303C5-07E9-454F-A45C-CDDCAAAED992Q40686762-174BD818-6B8D-49F0-9455-E9FD56E3E3CDQ41267193-CCCBF1B1-D025-45D4-AD79-E61FBCC24E27Q41928814-E6A61628-016F-4C5D-8FE7-60C383E16227Q42006192-2C2585B5-7E2E-46FE-864A-C54718D596E2Q42007327-C1613ADA-DE4E-4D5B-848C-5EC9147559F1Q42503313-01C74FE2-0ACD-444A-BD78-EA43BAB7C6D1Q45419445-E5A8EA1A-B6F5-4BEE-A45D-3D0DD97C81ACQ46246670-2E28A2CA-5B91-45CE-8BD0-EE92609ABC8DQ50145999-FD7243B0-FF79-4C57-9E8D-519C3D989ACCQ51405815-50DEDB19-6AB5-461A-9E4F-3FB54C944C05Q51680781-74055E6E-0930-4515-A8E7-D343D359BAAEQ51705517-23D7312C-E227-4DB9-83EF-BF06172C63A5Q57492451-8E5B8AB5-33A6-4ED6-91B1-8907E4D5B91F
P2860
A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A pharmacokinetic-pharmacodyna ...... c progenitor cells by AMD3100.
@en
A pharmacokinetic-pharmacodyna ...... c progenitor cells by AMD3100.
@nl
type
label
A pharmacokinetic-pharmacodyna ...... c progenitor cells by AMD3100.
@en
A pharmacokinetic-pharmacodyna ...... c progenitor cells by AMD3100.
@nl
prefLabel
A pharmacokinetic-pharmacodyna ...... c progenitor cells by AMD3100.
@en
A pharmacokinetic-pharmacodyna ...... c progenitor cells by AMD3100.
@nl
P2093
P1476
A pharmacokinetic-pharmacodyna ...... c progenitor cells by AMD3100.
@en
P2093
Calandra GB
MacFarland RT
P304
P356
10.1016/J.CLPT.2004.12.268
P407
P577
2005-05-01T00:00:00Z